Institute of Hygiene and Environmental Medicine, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Interdisciplinary workgroup on PVL-positive S. aureus (www.pvl-abszess.de), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
PLoS One. 2021 Jun 25;16(6):e0253633. doi: 10.1371/journal.pone.0253633. eCollection 2021.
Skin and soft tissue infections (SSTI) caused by Panton-Valentine leukocidin (PVL)-producing strains of Staphylococcus aureus (PVL-SA) are associated with recurrent skin abscesses. Secondary prevention, in conjunction with primary treatment of the infection, focuses on topical decolonization. Topical decolonization is a standard procedure in cases of recurrent PVL-SA skin infections and is recommended in international guidelines. However, this outpatient treatment is often not fully reimbursed by health insurance providers, which may interfere with successful PVL-SA decolonization.
Our goal was to estimate the cost effectiveness of outpatient decolonization of patients with recurrent PVL-SA skin infections. We calculated the average cost of treatment for PVL-SA per outpatient decolonization procedure as well as per in-hospital stay.
The study was conducted between 2014 and 2018 at a German tertiary care university hospital. The cohort analyzed was obtained from the hospital's microbiology laboratory database. Data on medical costs, DRG-based diagnoses, and ICD-10 patient data was obtained from the hospital's financial controlling department. We calculated the average cost of treatment for patients admitted for treatment of PVL-SA induced skin infections. The cost of outpatient treatment is based on the German regulations of drug prices for prescription drugs.
We analyzed a total of n = 466 swabs from n = 411 patients with recurrent skin infections suspected of carrying PVL-SA. PVL-SA was detected in 61.3% of all patients included in the study. Of those isolates, 80.6% were methicillin-susceptible, 19.4% methicillin-resistant. 89.8% of all patients were treated as outpatients. In 73.0% of inpatients colonized with PVL-SA the main diagnosis was SSTI. The median length of stay was 5.5 days for inpatients colonized with PVL-SA whose main diagnosis SSTI; the average cost was €2,283. The estimated costs per decolonization procedure in outpatients ranged from €50-€110, depending on the products used.
Our data shows that outpatient decolonization offers a highly cost-effective secondary prevention strategy, which may prevent costly inpatient treatments. Therefore, health insurance companies should consider providing coverage of outpatient treatment of recurrent PVL-SA skin and soft tissue infections.
金黄色葡萄球菌(PVL-SA)产生的抗药性杀白细胞素(PVL)导致的皮肤和软组织感染(SSTI)与复发性皮肤脓肿有关。二级预防与感染的主要治疗相结合,侧重于局部去定植。局部去定植是复发性 PVL-SA 皮肤感染的标准程序,国际指南建议使用。然而,这种门诊治疗往往不能完全由健康保险公司报销,这可能会影响成功的 PVL-SA 去定植。
我们的目标是评估复发性 PVL-SA 皮肤感染患者门诊去定植的成本效益。我们计算了每个门诊去定植程序以及每次住院治疗的 PVL-SA 治疗的平均费用。
该研究于 2014 年至 2018 年在德国一所三级护理大学医院进行。从医院的微生物学实验室数据库中获得了分析的队列。从医院的财务控制部门获得了医疗费用、基于诊断相关组(DRG)的诊断和国际疾病分类(ICD-10)患者数据。我们计算了因治疗 PVL-SA 引起的皮肤感染而住院的患者的平均治疗费用。门诊治疗的费用基于德国处方药价格的规定。
我们分析了来自 411 名疑似携带 PVL-SA 的复发性皮肤感染患者的 466 份拭子,共 466 份。在所有纳入研究的患者中,PVL-SA 的检出率为 61.3%。在这些分离株中,80.6%为甲氧西林敏感,19.4%为耐甲氧西林。所有患者中有 89.8%作为门诊患者接受治疗。在 73.0%的 PVL-SA 定植的住院患者中,主要诊断为 SSTI。主要诊断为 SSTI 的 PVL-SA 定植住院患者的中位住院时间为 5.5 天,平均费用为 2283 欧元。根据所用产品的不同,门诊患者每次去定植的估计费用为 50-110 欧元。
我们的数据表明,门诊去定植是一种具有高度成本效益的二级预防策略,可以预防昂贵的住院治疗。因此,健康保险公司应考虑为复发性 PVL-SA 皮肤和软组织感染的门诊治疗提供保险。